<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351819</url>
  </required_header>
  <id_info>
    <org_study_id>H-27995</org_study_id>
    <nct_id>NCT00351819</nct_id>
  </id_info>
  <brief_title>Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception</brief_title>
  <acronym>TAP</acronym>
  <official_title>Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Naturally occurring opiates (endorphins) decrease testosterone levels by inhibiting the
      synthesis of gonadotropin releasing hormone (GnRH) and also inhibiting testosterone synthesis
      by the testes. Similarly, men with addiction to narcotics and those on exogenous opioids for
      pain control have decreased serum testosterone levels. Indeed, these men complain of
      decreased libido, erectile dysfunction and impaired quality of life. Animal studies have
      shown that gonadectomy results in a decrease in pain threshold in rats and repletion of
      testosterone elevates that threshold. These observations suggest that testosterone may
      possess analgesic properties. Hence, the investigators hypothesize that hypogonadism
      developing in men on opioids results in an increased sensitivity to pain and requirement of
      higher doses of opioids. In this study, the investigators plan to administer testosterone to
      men with opioid-induced hypogonadism and evaluate their pain perception, pain sensitivity in
      response to noxious stimuli and changes in the requirement of opioids in response to
      testosterone administration.

      Hypothesis:

      Testosterone replacement in men with opioid-induced hypogonadism will improve pain tolerance,
      pain perception and quality of life.

      Specific aims:

        1. To evaluate the effects of testosterone replacement on pain sensitivity, pain tolerance,
           and pain modulation in men with opioid-induced hypogonadism.

        2. To determine the effects of testosterone replacement on health-related quality of life.

        3. To determine whether testosterone replacement in hypogonadal men induces changes in the
           dosage requirements of opioid medications for pain control.

      To accomplish our specific aims, the investigators propose a randomized, double blind,
      placebo-controlled, parallel arm study in which hypogonadal men with non-cancer chronic back
      pain syndrome on chronic opioids and low testosterone levels (&lt;300 ng/dl) will be randomized
      to exogenous testosterone replacement therapy vs placebo. Our primary outcome is change in
      pain tolerance using various external painful stimuli. Secondary outcomes are change in pain
      sensitivity and modulation, quality of life and opioid requirements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI) at Week 14</measure>
    <time_frame>Week14 after intervention</time_frame>
    <description>BPI is a self-administered questionnaire that measuring chronic pain. BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score assesses the severity of pain on a continuous scale from 0 (no pain) to 10 (severe pain). The pain interference score corresponds to the item on pain interference, ranging from 0 (does not interfere) to 10(completely interferes). The total score is the sum of the pain severity score and pain interference score, ranging from 0(no pain) to 20 (severe and completely interfered pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Algometer-induced Pressure Pain at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>A digital pressure algometer at the trapezius muscle and the metacarpophalangeal joint of the thumb was used to measure pressure pain thresholds. Higher values represent a better tolerance of pressure pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted Pinprick Stimulator-induced Mechanical Pain at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Weighted pinprick stimulators are used to assess mechanical pain. Lower values represent better tolerance of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ice Water-induced Cold Pain and Its After-sensation at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Cold-pressor tests measure cold-induced pain and its sensation. Time was measured when a participant reached pain tolerance in cold water and after sensation. Higher values of time in Cold pain tolerance and lower values of time in Cold pain after-sensation (30 seconds) represent better tolerance of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual Functioning as Assessed by International Index of Erectile Function (IIEF) at Week 14</measure>
    <time_frame>Week14 after intervention</time_frame>
    <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36) at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Catastrophizing Scale (PCS) at Week 14</measure>
    <time_frame>Values at week 14 after intervention</time_frame>
    <description>PCS questionnaire measures self-assessment of pain catastrophizing. This questionnaire consists of 13 items on past painful experiences and rate on 5-point scales ranging from 0 (not at all) to 4 (all the time). The PCS yields three subscale scores assessing rumination (range 0-16), magnification (range 0-12), helplessness (range 0-24), and a composite score (sum of three domains, ranging 0-52). Higher score represents worse painful experiences.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Testosterone Values at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Total testosterone was measured in a CDC-certified laboratory using an LC-MS/MS method with a sensitivity of 2 ng/dL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Free Testosterone Values at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Free testosterone was calculated using a law of mass action equation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex Hormone Binding Globulin (SHBG) at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Sex hormone binding globulin was measured using immunofluorometric assays, with limits of quantification of 2.5 nmol/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>Luteinizing Hormone Values at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Luteinizing hormone was measured using immunofluorometric assays, with limits of quantification of 0.05 U/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory Cytokines at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>The pathophysiology of pain is measured by the proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-Alpha).</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Composition at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Body composition was measured using dual-energy X-ray absorptiometry scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid Profile at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Serum total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol levels were measured by enzymatic assays and standardized to the CDC using the Lipid Research Clinic protocol. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation.</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose Level in Oral Glucose Tolerance Test (OGTT) at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The plasma glucose level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin Level in Oral Glucose Tolerance Test (OGTT) at Week 14</measure>
    <time_frame>Values at week 14 after intervention</time_frame>
    <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The insulin level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
  </other_outcome>
  <other_outcome>
    <measure>HOMA IR Score at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Insulin resistance was calculated using the homeostatic model assessment (HOMA) index: glucose * insulin / 22.5.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adiponectin at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Total adiponectin was measured using an RIA kit with an interassay CV of 6.9-9.3% and an intra-assay CV of 1.8-6.2% (Millipore).</description>
  </other_outcome>
  <other_outcome>
    <measure>Leptin at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>Leptin levels were measured using ELISA with an interassay CV of 2.6% to 6.2% and in intra-assay CV of 2.6% to 4.6% (Millipore, Billerica, MA, USA).</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive Protein (CRP) at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>High-sensitivity C-reactive protein (Alpco Diagnostics) was measured using a high-sensitivity sandwich ELISA with an intra-assay CV of 5.6%</description>
  </other_outcome>
  <other_outcome>
    <measure>Insomnia Severity Index (ISI) at Week 14</measure>
    <time_frame>Week 14 after intervention</time_frame>
    <description>ISI is comprised of 7 items assesses a participant's perception of insomnia. Each item is rated on a 5-point scale from 0 (none) to 4 (very severe). Scores from the questions are summed to assign a total score ranging from 0 to 28, where higher score represents worse insomnia problem.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Pain</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Androgel (testosterone gel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel</intervention_name>
    <description>5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
    <arm_group_label>Androgel (testosterone gel)</arm_group_label>
    <other_name>testosterone gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men

          -  Age 18 years and older

          -  Non-cancer chronic pain

          -  Serum total testosterone level &lt;350 ng/dl

          -  Consumption of at least 20 mg of hydrocodone (or analgesic equivalent of another
             opioid) for at least 4 weeks

          -  Absence of hospitalization in the past 2 months

          -  No acute illness in the past 2 months

          -  No current anabolic therapy (growth hormone, DHEA, etc)

          -  No current use or consumption in the past 2 months of melatonin

          -  Normal prostate exam

          -  Normal PSA level

        Exclusion Criteria:

          -  Cancer-related chronic pain

          -  Liver enzymes &gt; 3 times upper limit of normal

          -  Serum creatinine &gt; 2 times upper limit of normal

          -  Neurological disease

          -  Active psychiatric illness

          -  Any addictive drug use

          -  Alcoholism (&gt;3 drinks/day)

          -  Patients currently receiving melatonin or anabolic agents

          -  Hospitalization in the past 2 months

          -  Acute illness in the past 2 months

          -  Consumption of &lt; 20 mg of hydrocodone (or analgesic equivalent of another opioid)

          -  Severe BPH

          -  PSA &gt; 4.0 ng/ml

          -  Prostate cancer

          -  Breast cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shehzad Basaria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2006</study_first_submitted>
  <study_first_submitted_qc>July 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2006</study_first_posted>
  <results_first_submitted>March 24, 2017</results_first_submitted>
  <results_first_submitted_qc>May 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Shehzad Basaria</investigator_full_name>
    <investigator_title>ASSOCIATE PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Pain</keyword>
  <keyword>Opioid</keyword>
  <keyword>Hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Androgel (Testosterone Gel)</title>
          <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elevated PSA</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Traumatic ankle fracture</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unprofessional behavior</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled in another trial</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Androgel (Testosterone Gel)</title>
          <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="9"/>
                    <measurement group_id="B2" value="50" spread="6"/>
                    <measurement group_id="B3" value="49" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="7.0"/>
                    <measurement group_id="B2" value="33.4" spread="8.0"/>
                    <measurement group_id="B3" value="32.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Opioid dose (morphine equivalent)</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114" spread="176"/>
                    <measurement group_id="B2" value="76" spread="139"/>
                    <measurement group_id="B3" value="97" spread="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on opioids</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="48"/>
                    <measurement group_id="B2" value="40" spread="54"/>
                    <measurement group_id="B3" value="48" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221" spread="87"/>
                    <measurement group_id="B2" value="237" spread="97"/>
                    <measurement group_id="B3" value="228" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free testosterone</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="22.6"/>
                    <measurement group_id="B2" value="43.6" spread="19.3"/>
                    <measurement group_id="B3" value="43.9" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex hormone binding globulin</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="31.4"/>
                    <measurement group_id="B2" value="37.7" spread="14.5"/>
                    <measurement group_id="B3" value="38.6" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Luteinizing hormone</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.9"/>
                    <measurement group_id="B2" value="3.8" spread="2.4"/>
                    <measurement group_id="B3" value="3.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNF-Alpha</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.6"/>
                    <measurement group_id="B2" value="2.2" spread="2.7"/>
                    <measurement group_id="B3" value="2.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL-6</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="2.8"/>
                    <measurement group_id="B2" value="2.8" spread="2.9"/>
                    <measurement group_id="B3" value="2.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="B2" value="14" lower_limit="13" upper_limit="15"/>
                    <measurement group_id="B3" value="15" lower_limit="13" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="40" upper_limit="46"/>
                    <measurement group_id="B2" value="43" lower_limit="39" upper_limit="45"/>
                    <measurement group_id="B3" value="43" lower_limit="40" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory (BPI) questionnaire</title>
          <description>The Brief Pain Inventory (BPI) is a self-administered questionnaire that measuring chronic pain. The BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score assesses the severity of pain on a continuous scale from 0 (no pain) to 10 (severe pain). The pain interference score corresponds to the item on pain interference, ranging from 0 (does not interfere) to 10(completely interferes). The total score (ranging from 0-20) is the sum of the pain severity score and pain interference score. Higher scores represents severer and more interfering pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="3.2"/>
                    <measurement group_id="B2" value="10.4" spread="3.1"/>
                    <measurement group_id="B3" value="11.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.5"/>
                    <measurement group_id="B2" value="5.5" spread="1.7"/>
                    <measurement group_id="B3" value="5.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="2.2"/>
                    <measurement group_id="B2" value="4.9" spread="1.8"/>
                    <measurement group_id="B3" value="5.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Algometer-induced pressure pain</title>
          <description>A digital pressure algometer at the trapezius muscle and the metacarpophalangeal joint of the thumb was used to measure pressure pain thresholds. Higher values represent a better tolerance of pressure pain.</description>
          <units>kPa/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trapezius</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341" spread="116"/>
                    <measurement group_id="B2" value="353" spread="197"/>
                    <measurement group_id="B3" value="347" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thumb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="369" spread="125"/>
                    <measurement group_id="B2" value="383" spread="185"/>
                    <measurement group_id="B3" value="375" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weighted pinprick stimulator-induced mechanical pain</title>
          <description>Weighted pinprick stimulators are used to assess mechanical pain. Lower values represent better tolerance of pain.</description>
          <units>watt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>First stimulus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" spread="13.0"/>
                    <measurement group_id="B2" value="8.0" spread="7.4"/>
                    <measurement group_id="B3" value="10.2" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th stimulus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="20.6"/>
                    <measurement group_id="B2" value="18.6" spread="19.5"/>
                    <measurement group_id="B3" value="23.2" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ice water-induced cold pain and its after-sensation</title>
          <description>Cold-pressor tests measure cold-induced pain and its sensation. Time was measured when a participant reached pain tolerance in cold water and after sensation. Higher values of time in Cold pain tolerance and lower values of time in Cold pain after-sensation (30 seconds) represent better tolerance of pain.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Cold pain tolerance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="33.4"/>
                    <measurement group_id="B2" value="53.3" spread="51.3"/>
                    <measurement group_id="B3" value="46.1" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold pain after sensation: 30s</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.7" spread="19.2"/>
                    <measurement group_id="B2" value="13.8" spread="18.0"/>
                    <measurement group_id="B3" value="15.4" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sexual Function as assessed by International Index of Erectile Function (IIEF)</title>
          <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="19.0"/>
                    <measurement group_id="B2" value="41.1" spread="21.7"/>
                    <measurement group_id="B3" value="43.0" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile function</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="9.2"/>
                    <measurement group_id="B2" value="16.8" spread="10.6"/>
                    <measurement group_id="B3" value="17.9" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic function</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="3.5"/>
                    <measurement group_id="B2" value="6.1" spread="3.6"/>
                    <measurement group_id="B3" value="6.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="2.5"/>
                    <measurement group_id="B2" value="6.2" spread="2.1"/>
                    <measurement group_id="B3" value="5.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="4.6"/>
                    <measurement group_id="B2" value="7.1" spread="5.6"/>
                    <measurement group_id="B3" value="7.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="2.5"/>
                    <measurement group_id="B2" value="5.0" spread="2.9"/>
                    <measurement group_id="B3" value="4.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Quality of Life (QoL) as assessed by Short Form 36 (SF-36)</title>
          <description>The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="22"/>
                    <measurement group_id="B2" value="38" spread="25"/>
                    <measurement group_id="B3" value="39" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="15"/>
                    <measurement group_id="B2" value="55" spread="17"/>
                    <measurement group_id="B3" value="56" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="24"/>
                    <measurement group_id="B2" value="18" spread="31"/>
                    <measurement group_id="B3" value="13" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="45"/>
                    <measurement group_id="B2" value="40" spread="45"/>
                    <measurement group_id="B3" value="39" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="16"/>
                    <measurement group_id="B2" value="59" spread="17"/>
                    <measurement group_id="B3" value="60" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="13"/>
                    <measurement group_id="B2" value="54" spread="15"/>
                    <measurement group_id="B3" value="54" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energry/fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="18"/>
                    <measurement group_id="B2" value="37" spread="18"/>
                    <measurement group_id="B3" value="37" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perceptions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="14"/>
                    <measurement group_id="B2" value="51" spread="14"/>
                    <measurement group_id="B3" value="52" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body composition measured by dual energy x-ray absorptiometry</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lean mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="7.8"/>
                    <measurement group_id="B2" value="60.1" spread="6.9"/>
                    <measurement group_id="B3" value="58.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fat mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="9.7"/>
                    <measurement group_id="B2" value="26.8" spread="9.5"/>
                    <measurement group_id="B3" value="26.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.4" spread="16.1"/>
                    <measurement group_id="B2" value="86.8" spread="13.8"/>
                    <measurement group_id="B3" value="85.5" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular lean mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="4.0"/>
                    <measurement group_id="B2" value="28.6" spread="4.2"/>
                    <measurement group_id="B3" value="27.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular fat mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="4.9"/>
                    <measurement group_id="B2" value="11.9" spread="5.1"/>
                    <measurement group_id="B3" value="11.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular total mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="7.8"/>
                    <measurement group_id="B2" value="39.4" spread="7.0"/>
                    <measurement group_id="B3" value="38.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid profile</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.1"/>
                    <measurement group_id="B2" value="5.2" spread="1.2"/>
                    <measurement group_id="B3" value="4.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.0"/>
                    <measurement group_id="B2" value="3.2" spread="0.9"/>
                    <measurement group_id="B3" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.3"/>
                    <measurement group_id="B2" value="1.1" spread="0.4"/>
                    <measurement group_id="B3" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="1.6"/>
                    <measurement group_id="B2" value="2.0" spread="1.2"/>
                    <measurement group_id="B3" value="2.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycossylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.01"/>
                    <measurement group_id="B2" value="6.2" spread="0.02"/>
                    <measurement group_id="B3" value="5.9" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose levels in OGTT</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Fasting glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="0.7"/>
                    <measurement group_id="B2" value="5.6" spread="2.6"/>
                    <measurement group_id="B3" value="5.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 1-h glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="2.9"/>
                    <measurement group_id="B2" value="8.0" spread="2.8"/>
                    <measurement group_id="B3" value="8.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 2-h glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="1.9"/>
                    <measurement group_id="B2" value="6.0" spread="2.0"/>
                    <measurement group_id="B3" value="6.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin levels in OGTT</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Fasting insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="66"/>
                    <measurement group_id="B2" value="100" spread="174"/>
                    <measurement group_id="B3" value="80" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 1-h insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300" spread="306"/>
                    <measurement group_id="B2" value="416" spread="325"/>
                    <measurement group_id="B3" value="351" spread="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 2-h insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246" spread="242"/>
                    <measurement group_id="B2" value="311" spread="293"/>
                    <measurement group_id="B3" value="275" spread="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA IR</title>
          <description>Homeostatic model assessment (HOMA) is a method for assessing -cell function and insulin resistance (IR) from basal (fasting) glucose and insulin. HOMA IR was calculated using the formula: glucose * insulin / 22.5</description>
          <units>HOMA IR score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="2.1"/>
                    <measurement group_id="B2" value="3.3" spread="5.8"/>
                    <measurement group_id="B3" value="2.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <population>Of the completers, 64 men (36 in the testosterone arm and 28 in the placebo arm) had pre and post-intervention data on Adiponectin outcomes.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="2.7"/>
                    <measurement group_id="B2" value="4.5" spread="1.7"/>
                    <measurement group_id="B3" value="4.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leptin</title>
          <population>Of the completers, 64 men (36 in the testosterone arm and 28 in the placebo arm) had pre and post-intervention data on Leptin outcomes.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="12"/>
                    <measurement group_id="B2" value="18" spread="17"/>
                    <measurement group_id="B3" value="17" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein</title>
          <population>Of the completers, 64 men (36 in the testosterone arm and 28 in the placebo arm) had pre and post-intervention data on C-reactive protein outcomes.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="3.5"/>
                    <measurement group_id="B2" value="2.7" spread="2.3"/>
                    <measurement group_id="B3" value="2.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain catastrophizing scale (PCS)</title>
          <description>PCS questionnaire measures self-assessment of pain catastrophizing. This questionnaire consists of 13 items on past painful experiences and rate on 5-point scales ranging from 0 (not at all) to 4 (all the time). The PCS yields three subscale scores assessing rumination (range 0-16), magnification (range 0-12), helplessness (range 0-24), and a composite score (sum of three domains, ranging 0-52). Higher score represents worse painful experiences.</description>
          <population>Of the completers, 62 men (33 in the testosterone arm and 29 in the placebo arm) had pre and post-intervention data on PCS outcomes.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Composite score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="11"/>
                    <measurement group_id="B2" value="27" spread="11"/>
                    <measurement group_id="B3" value="27" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rumination score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="4.0"/>
                    <measurement group_id="B2" value="9.6" spread="3.0"/>
                    <measurement group_id="B3" value="9.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnification score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="3.2"/>
                    <measurement group_id="B2" value="5.1" spread="2.9"/>
                    <measurement group_id="B3" value="4.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helplessness score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="5.3"/>
                    <measurement group_id="B2" value="11.6" spread="5.1"/>
                    <measurement group_id="B3" value="11.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia severity index (ISI)</title>
          <description>ISI is comprised of 7 items assesses a participant's perception of insomnia that specifically address the symptoms and consequences of insomnia, as well as the degree of distress caused by sleep quality. Each item is rated on a 5-point scale from 0 (none) to 4 (very severe). Scores from the questions are summed to assign a total score ranging from 0 to 28, where higher score represents worse insomnia problem.</description>
          <population>Of the completers, 62 men (33 in the testosterone arm and 29 in the placebo arm) had pre and post-intervention data on ISI outcomes.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="4.7"/>
                    <measurement group_id="B2" value="11.6" spread="4.4"/>
                    <measurement group_id="B3" value="11.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brief Pain Inventory (BPI) at Week 14</title>
        <description>BPI is a self-administered questionnaire that measuring chronic pain. BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score assesses the severity of pain on a continuous scale from 0 (no pain) to 10 (severe pain). The pain interference score corresponds to the item on pain interference, ranging from 0 (does not interfere) to 10(completely interferes). The total score is the sum of the pain severity score and pain interference score, ranging from 0(no pain) to 20 (severe and completely interfered pain).</description>
        <time_frame>Week14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) at Week 14</title>
          <description>BPI is a self-administered questionnaire that measuring chronic pain. BPI gives two main scores: a pain severity score and a pain interference score. The pain severity score assesses the severity of pain on a continuous scale from 0 (no pain) to 10 (severe pain). The pain interference score corresponds to the item on pain interference, ranging from 0 (does not interfere) to 10(completely interferes). The total score is the sum of the pain severity score and pain interference score, ranging from 0(no pain) to 20 (severe and completely interfered pain).</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.8"/>
                    <measurement group_id="O2" value="9.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.7"/>
                    <measurement group_id="O2" value="5.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.3"/>
                    <measurement group_id="O2" value="4.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Algometer-induced Pressure Pain at Week 14</title>
        <description>A digital pressure algometer at the trapezius muscle and the metacarpophalangeal joint of the thumb was used to measure pressure pain thresholds. Higher values represent a better tolerance of pressure pain.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Algometer-induced Pressure Pain at Week 14</title>
          <description>A digital pressure algometer at the trapezius muscle and the metacarpophalangeal joint of the thumb was used to measure pressure pain thresholds. Higher values represent a better tolerance of pressure pain.</description>
          <units>kPa/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trapezius</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.4" spread="194.7"/>
                    <measurement group_id="O2" value="315.9" spread="151.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thumb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.7" spread="167.9"/>
                    <measurement group_id="O2" value="326.4" spread="187.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weighted Pinprick Stimulator-induced Mechanical Pain at Week 14</title>
        <description>Weighted pinprick stimulators are used to assess mechanical pain. Lower values represent better tolerance of pain.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Pinprick Stimulator-induced Mechanical Pain at Week 14</title>
          <description>Weighted pinprick stimulators are used to assess mechanical pain. Lower values represent better tolerance of pain.</description>
          <units>watts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Stimulus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="8.4"/>
                    <measurement group_id="O2" value="11.7" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th Stimulus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="17.4"/>
                    <measurement group_id="O2" value="22.2" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ice Water-induced Cold Pain and Its After-sensation at Week 14</title>
        <description>Cold-pressor tests measure cold-induced pain and its sensation. Time was measured when a participant reached pain tolerance in cold water and after sensation. Higher values of time in Cold pain tolerance and lower values of time in Cold pain after-sensation (30 seconds) represent better tolerance of pain.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Ice Water-induced Cold Pain and Its After-sensation at Week 14</title>
          <description>Cold-pressor tests measure cold-induced pain and its sensation. Time was measured when a participant reached pain tolerance in cold water and after sensation. Higher values of time in Cold pain tolerance and lower values of time in Cold pain after-sensation (30 seconds) represent better tolerance of pain.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold pain tolenrance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="55.9"/>
                    <measurement group_id="O2" value="54.1" spread="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold pain after sensation: 30s</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="18.4"/>
                    <measurement group_id="O2" value="13.9" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Functioning as Assessed by International Index of Erectile Function (IIEF) at Week 14</title>
        <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
        <time_frame>Week14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Functioning as Assessed by International Index of Erectile Function (IIEF) at Week 14</title>
          <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="17.5"/>
                    <measurement group_id="O2" value="47.1" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="7.9"/>
                    <measurement group_id="O2" value="19.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic funcion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="2.9"/>
                    <measurement group_id="O2" value="6.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.1"/>
                    <measurement group_id="O2" value="6.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="5.2"/>
                    <measurement group_id="O2" value="9.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.5"/>
                    <measurement group_id="O2" value="6.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36) at Week 14</title>
        <description>The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36) at Week 14</title>
          <description>The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="19"/>
                    <measurement group_id="O2" value="42" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="21"/>
                    <measurement group_id="O2" value="61" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="35"/>
                    <measurement group_id="O2" value="22" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="42"/>
                    <measurement group_id="O2" value="37" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="16"/>
                    <measurement group_id="O2" value="63" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="14"/>
                    <measurement group_id="O2" value="54" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy-fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="17"/>
                    <measurement group_id="O2" value="40" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health perceptions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="12"/>
                    <measurement group_id="O2" value="52" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Catastrophizing Scale (PCS) at Week 14</title>
        <description>PCS questionnaire measures self-assessment of pain catastrophizing. This questionnaire consists of 13 items on past painful experiences and rate on 5-point scales ranging from 0 (not at all) to 4 (all the time). The PCS yields three subscale scores assessing rumination (range 0-16), magnification (range 0-12), helplessness (range 0-24), and a composite score (sum of three domains, ranging 0-52). Higher score represents worse painful experiences.</description>
        <time_frame>Values at week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Catastrophizing Scale (PCS) at Week 14</title>
          <description>PCS questionnaire measures self-assessment of pain catastrophizing. This questionnaire consists of 13 items on past painful experiences and rate on 5-point scales ranging from 0 (not at all) to 4 (all the time). The PCS yields three subscale scores assessing rumination (range 0-16), magnification (range 0-12), helplessness (range 0-24), and a composite score (sum of three domains, ranging 0-52). Higher score represents worse painful experiences.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="12"/>
                    <measurement group_id="O2" value="21" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rumination score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.1"/>
                    <measurement group_id="O2" value="7.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnification score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.8"/>
                    <measurement group_id="O2" value="4.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helplessness score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="5.8"/>
                    <measurement group_id="O2" value="8.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Testosterone Values at Week 14</title>
        <description>Total testosterone was measured in a CDC-certified laboratory using an LC-MS/MS method with a sensitivity of 2 ng/dL.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone Values at Week 14</title>
          <description>Total testosterone was measured in a CDC-certified laboratory using an LC-MS/MS method with a sensitivity of 2 ng/dL.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="790" spread="544"/>
                    <measurement group_id="O2" value="328" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Free Testosterone Values at Week 14</title>
        <description>Free testosterone was calculated using a law of mass action equation.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Testosterone Values at Week 14</title>
          <description>Free testosterone was calculated using a law of mass action equation.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="152"/>
                    <measurement group_id="O2" value="65" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sex Hormone Binding Globulin (SHBG) at Week 14</title>
        <description>Sex hormone binding globulin was measured using immunofluorometric assays, with limits of quantification of 2.5 nmol/L.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Sex Hormone Binding Globulin (SHBG) at Week 14</title>
          <description>Sex hormone binding globulin was measured using immunofluorometric assays, with limits of quantification of 2.5 nmol/L.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="18.2"/>
                    <measurement group_id="O2" value="35.0" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Luteinizing Hormone Values at Week 14</title>
        <description>Luteinizing hormone was measured using immunofluorometric assays, with limits of quantification of 0.05 U/L.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone Values at Week 14</title>
          <description>Luteinizing hormone was measured using immunofluorometric assays, with limits of quantification of 0.05 U/L.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.2"/>
                    <measurement group_id="O2" value="3.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Inflammatory Cytokines at Week 14</title>
        <description>The pathophysiology of pain is measured by the proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-Alpha).</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Cytokines at Week 14</title>
          <description>The pathophysiology of pain is measured by the proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-Alpha).</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.1"/>
                    <measurement group_id="O2" value="2.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-Alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.0"/>
                    <measurement group_id="O2" value="2.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Body Composition at Week 14</title>
        <description>Body composition was measured using dual-energy X-ray absorptiometry scan.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition at Week 14</title>
          <description>Body composition was measured using dual-energy X-ray absorptiometry scan.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lean mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" spread="7.5"/>
                    <measurement group_id="O2" value="60.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="8.7"/>
                    <measurement group_id="O2" value="27.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="14.8"/>
                    <measurement group_id="O2" value="88.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular lean mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="4.1"/>
                    <measurement group_id="O2" value="29.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="4.7"/>
                    <measurement group_id="O2" value="12.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular total mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="7.9"/>
                    <measurement group_id="O2" value="40.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lipid Profile at Week 14</title>
        <description>Serum total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol levels were measured by enzymatic assays and standardized to the CDC using the Lipid Research Clinic protocol. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile at Week 14</title>
          <description>Serum total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol levels were measured by enzymatic assays and standardized to the CDC using the Lipid Research Clinic protocol. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.2"/>
                    <measurement group_id="O2" value="5.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.4"/>
                    <measurement group_id="O2" value="1.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.0"/>
                    <measurement group_id="O2" value="1.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>HbA1c at Week 14</title>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c at Week 14</title>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>percentage of glycosylated hemogobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.01"/>
                    <measurement group_id="O2" value="6.1" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Glucose Level in Oral Glucose Tolerance Test (OGTT) at Week 14</title>
        <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The plasma glucose level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Level in Oral Glucose Tolerance Test (OGTT) at Week 14</title>
          <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The plasma glucose level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.4"/>
                    <measurement group_id="O2" value="5.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 1-h glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="3.4"/>
                    <measurement group_id="O2" value="8.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 2-h glucose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="3.2"/>
                    <measurement group_id="O2" value="6.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Insulin Level in Oral Glucose Tolerance Test (OGTT) at Week 14</title>
        <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The insulin level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
        <time_frame>Values at week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Level in Oral Glucose Tolerance Test (OGTT) at Week 14</title>
          <description>All participants underwent 75-g oral glucose tolerance test (OGTT) after a 12-h fast, The insulin level were analyzed at baseline and at 60 and 120 min after glucose loading.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="88"/>
                    <measurement group_id="O2" value="110" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 1-h insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" spread="181"/>
                    <measurement group_id="O2" value="407" spread="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OGTT 2-h insulin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="210"/>
                    <measurement group_id="O2" value="325" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>HOMA IR Score at Week 14</title>
        <description>Insulin resistance was calculated using the homeostatic model assessment (HOMA) index: glucose * insulin / 22.5.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>HOMA IR Score at Week 14</title>
          <description>Insulin resistance was calculated using the homeostatic model assessment (HOMA) index: glucose * insulin / 22.5.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>HOMA IR score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.6"/>
                    <measurement group_id="O2" value="4.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adiponectin at Week 14</title>
        <description>Total adiponectin was measured using an RIA kit with an interassay CV of 6.9-9.3% and an intra-assay CV of 1.8-6.2% (Millipore).</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin at Week 14</title>
          <description>Total adiponectin was measured using an RIA kit with an interassay CV of 6.9-9.3% and an intra-assay CV of 1.8-6.2% (Millipore).</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.0"/>
                    <measurement group_id="O2" value="4.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Leptin at Week 14</title>
        <description>Leptin levels were measured using ELISA with an interassay CV of 2.6% to 6.2% and in intra-assay CV of 2.6% to 4.6% (Millipore, Billerica, MA, USA).</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin at Week 14</title>
          <description>Leptin levels were measured using ELISA with an interassay CV of 2.6% to 6.2% and in intra-assay CV of 2.6% to 4.6% (Millipore, Billerica, MA, USA).</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="12"/>
                    <measurement group_id="O2" value="21" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>C-reactive Protein (CRP) at Week 14</title>
        <description>High-sensitivity C-reactive protein (Alpco Diagnostics) was measured using a high-sensitivity sandwich ELISA with an intra-assay CV of 5.6%</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) at Week 14</title>
          <description>High-sensitivity C-reactive protein (Alpco Diagnostics) was measured using a high-sensitivity sandwich ELISA with an intra-assay CV of 5.6%</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="4.4"/>
                    <measurement group_id="O2" value="3.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Insomnia Severity Index (ISI) at Week 14</title>
        <description>ISI is comprised of 7 items assesses a participant's perception of insomnia. Each item is rated on a 5-point scale from 0 (none) to 4 (very severe). Scores from the questions are summed to assign a total score ranging from 0 to 28, where higher score represents worse insomnia problem.</description>
        <time_frame>Week 14 after intervention</time_frame>
        <population>All available data expressed as absolute values at week 14.</population>
        <group_list>
          <group group_id="O1">
            <title>Androgel (Testosterone Gel)</title>
            <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index (ISI) at Week 14</title>
          <description>ISI is comprised of 7 items assesses a participant's perception of insomnia. Each item is rated on a 5-point scale from 0 (none) to 4 (very severe). Scores from the questions are summed to assign a total score ranging from 0 to 28, where higher score represents worse insomnia problem.</description>
          <population>All available data expressed as absolute values at week 14.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.2"/>
                    <measurement group_id="O2" value="11.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Androgel (Testosterone Gel)</title>
          <description>Testosterone replacement therapy
Androgel (testosterone gel): 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo gel
Placebo: 5g gel, applied once daily to the upper arms, upper back or shoulders.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Wrist arthrodesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shehzad Basaria</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-9150</phone>
      <email>sbasaria@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

